Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Kezia Gaitskell, Ewelina Rogozińska, Sarah Platt...
https://pubmed.ncbi.nlm.nih.gov/37185961/Actively Recruiting
Led by AGO Study Group · Updated on 2025-09-10
970
Participants Needed
65
Research Sites
156 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of two treatment strategies for patients newly diagnosed with advanced ovarian, peritoneal, or fallopian tube cancer. This international, multicenter, randomized, open Phase III trial compares carboplatinpaclitaxel chemotherapy followed by niraparib alone versus carboplatinpaclitaxel combined with bevacizumab followed by both bevacizumab and niraparib. The study includes patients with high-grade, non-mucinous, non-clear cell epithelial tumors at specific advanced stages who have had surgery or plan chemotherapy with interval debulking surgery. All patients receive an initial cycle of carboplatin and paclitaxel before randomization. After central testing of tumor BRCA status, participants are randomly assigned to one of two arms Arm 1 continues with five more cycles of carboplatin and paclitaxel followed by daily niraparib for up to three years Arm 2 receives five cycles of carboplatin and paclitaxel plus bevacizumab, then maintenance bevacizumab for up to one year alongside daily niraparib for up to three years. This design aims to determine if adding bevacizumab improves outcomes over the standard treatment. Participants undergo frequent assessments including scans and laboratory tests to monitor progression-free survival and other health outcomes. Researchers also evaluate overall survival, time to additional therapies, treatment-related side effects, and quality of life up to several years after enrollment. Patients attend regular visits for treatment, monitoring, and completion of questionnaires, with safety follow-up 30 days after the last dose. The entire observation period can last up to 66 months after the last patient joins the trial.
CONDITIONS
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
S
Sandra Polleis
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AGO Study Group
Lead Sponsor
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 weeks
Participants receive the first cycle of chemotherapy with carboplatin and paclitaxel as part of the study run-in period while tumor BRCA status is determined.
1 visit for chemotherapy administration
Duration - Approximately 18 weeks for chemotherapy followed by up to 3 years of maintenance therapy
Participants are randomized to receive either chemotherapy alone followed by maintenance with niraparib, or chemotherapy combined with bevacizumab followed by maintenance with bevacizumab and niraparib.
6 chemotherapy visits every 3 weeks followed by regular visits during maintenance treatment
Duration - Up to 66 months after last patient in
Participants are monitored for progression-free survival, overall survival, adverse events, and quality of life up to 66 months after last patient enrollment.
Visits at every scheduled assessment during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kezia Gaitskell, Ewelina Rogozińska, Sarah Platt...
https://pubmed.ncbi.nlm.nih.gov/37185961/Florian Heitz, Christian Marth, Stéphanie Henry...
https://pubmed.ncbi.nlm.nih.gov/37935524/AGO Study Group
Lead Sponsor
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Collaborating Sponsor